Here are the DEF 14A proxy statements from Contineum Therapeutics, Inc. (CTNM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CTNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTNM filings page.
Contineum Therapeutics, Inc. is asking stockholders to vote at its fully virtual 2026 Annual Meeting on June 26, 2026 at 8:00 a.m. Pacific Time via webcast after advance registration at www.proxydocs.com/CTNM.
Stockholders will vote on electing three Class II directors—Evert Schimmelpennink, Lori M. Lyons‑Williams and Diego Miralles, M.D.—to serve until the 2029 annual meeting, and on ratifying Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. Only holders of the 32,723,877 shares of Class A common stock outstanding as of April 27, 2026 may vote, with one vote per share. The board recommends voting “FOR” all director nominees and “FOR” auditor ratification.